Blood test may predict who needs less immunotherapy after lung cancer surgery
NCT ID NCT06902272
First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time
Summary
This study is testing whether a blood test that looks for bits of tumor DNA (called ctDNA) can predict how well people with early-stage lung cancer respond to treatment. Researchers want to see if the test can identify patients who have no cancer left after chemotherapy and immunotherapy, so they might safely receive less immunotherapy after surgery. The trial involves about 30 adults with stage IB to IIIB non-small cell lung cancer who are scheduled for surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a blood test that measures circulating tumor DNA (ctDNA) to guide treatment decisions, along with the immunotherapy drug pembrolizumab
- What this could lead to
- If successful, this approach could allow some patients to receive less immunotherapy after surgery, reducing side effects while still preventing cancer from returning.
- What could go wrong
- This is a small, early-phase study, so results may not apply to all patients. The ctDNA test may not reliably predict outcomes, and reducing immunotherapy could increase the risk of cancer recurrence.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Miami
RECRUITINGMiami, Florida, 33136, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Chest-Injected drug drain Cancer's fluid trap?
- Can a radioactive tracer reveal whether immunotherapy is working?
- Can a new nucleotide analogue boost cancer treatment?
- Can a pill that blocks multiple cancer proteins shrink Hard-to-Treat tumors?
- Can a Two-Pronged attack shrink Hard-to-Treat cancers?
- Can standard cancer treatment wake up the immune system? a study investigates.